Evidence · Research paper
Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
- Allied health
- Infection
- Late-onset sepsis
- Medical
This paper is from 2018, more than five years ago. Newer evidence may have been published since.
Summary
Population pharmacokinetic analysis of meropenem in plasma and cerebrospinal fluid in neonates and young infants, using data from the NeoMero-1 (late-onset sepsis) and NeoMero-2 (meningitis) studies. It models clearance and volume with allometric scaling and maturation, and describes low CSF penetration that increases with CSF protein. Simulations explore how infusion duration affects plasma versus CSF target attainment, with relevance to dosing strategies for neonatal sepsis and meningitis.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.